Supplementary Figure S8 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Authors:
- Jörg WilludaJWJörg Willuda
- Lars LindenLLLars Linden
- Hans-Georg LerchenHLHans-Georg Lerchen
- Charlotte KopitzCKCharlotte Kopitz
- Beatrix Stelte-LudwigBSBeatrix Stelte-Ludwig
- Carol PenaCPCarol Pena
- Claudia LangeCLClaudia Lange
- Sven GolfierSGSven Golfier
- Christoph KneipCKChristoph Kneip
- Patricia E. CarriganPCPatricia E. Carrigan
- Kirk McleanKMKirk Mclean
- Joachim SchuhmacherJSJoachim Schuhmacher
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)